CLASS II ONGOING Device recall · Reported 29 Nov 2023 · FDA Enforcement Report

Tina-quant D-Dimer Test System recalled by Roche Diagnostics Operations

Roche Diagnostics Operations is recalling Tina-quant D-Dimer Test System, Fibrinogen/Fibrin Degradation Products Assay, Material, distributed nationwide in the US. The recall was initiated on 3 Oct 2023 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesAll Lots Affected. UDI: 04015630914593 - (cobas c 311, 501 and 502; INTEGRA 400 plus) UDI: 07613336133651 - (cobas c 303 and 503)
Quantity recalled5,263 kits

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-0352-2024
FDA event ID
93282
Recalling firm
Roche Diagnostics Operations, Indianapolis, IN
Classification
Class II
Status
Ongoing
Recall initiated
3 Oct 2023
FDA classified
20 Nov 2023
Reported
29 Nov 2023
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

3 Oct 2023Recall initiated by company
20 Nov 2023Classified by FDA+48 days
29 Nov 2023Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Elevated results were detected with Li-heparin plasma samples when compared to citrated plasma samples.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Tina-quant D-Dimer Test System, Fibrinogen/Fibrin Degradation Products Assay, Material Numbers 03001245322 - (cobas c 311, 501 and 502; INTEGRA 400 plus), 08105618190 - (cobas c 303 and 503)

Where it was distributed

US Nationwide distribution.

Nationwide

Questions about this recall

Why was it recalled?

Elevated results were detected with Li-heparin plasma samples when compared to citrated plasma samples.

Which lots are affected?

All Lots Affected. UDI: 04015630914593 - (cobas c 311, 501 and 502; INTEGRA 400 plus) UDI: 07613336133651 - (cobas c 303 and 503)

Where was it sold?

US Nationwide distribution.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Roche Diagnostics Operations

All 127

Other Test Kits & Diagnostics recalls

All 2,671